San Francisco-based Sirion Biotech and Germany company Denali Therapeutics will partner to develop next-generation adeno-associated viral vectors (AAV) aimed at treating neurodegenerative disorders such as Parkinson's and Alzheimer’s diseases. The companies hope their collaboration will speed up the marketing of AAV-based gene therapies, specifically more efficient AAV capsids, and ensure their availability to "many millions" of patients.
Germany-based Sirion Biotech and San Francisco company Denali Therapeutics will partner to develop next-generation adeno-associated viral vectors (AAV) aimed at treating neurodegenerative disorders such as Parkinson's and Alzheimer’s diseases. The companies hope their collaboration will speed up the marketing of AAV-based gene therapies, specifically more efficient AAV capsids, and ensure their availability to "many millions" of patients.